Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Nucleozin 靶向流感 A 核蛋白,这是一种病毒复制所必需的多功能 RNA 结合蛋白。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 287 | 现货 | ||
5 mg | ¥ 463 | 现货 | ||
10 mg | ¥ 743 | 现货 | ||
25 mg | ¥ 1,570 | 现货 | ||
50 mg | ¥ 2,380 | 现货 | ||
100 mg | ¥ 3,560 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 497 | 现货 |
产品描述 | Nucleozin targets influenza A nucleoprotein (NP), a multifunctional, RNA-binding protein necessary for virus replication. |
体外活性 | Nucleozin blocked the cytoplasmic trafficking of ribonucleoproteins (RNPs) that had undergone nuclear export, promoting the formation of large perinuclear aggregates of RNPs along with cellular Rab11. This effect led to the production of much reduced amounts of often markedly smaller virus particles. The primary target of nucleozin is the viral RNP. IAV replication can be effectively inhibited by blocking cytoplasmic trafficking of the viral genome[1]. |
体内活性 | Nucleozin, that triggers the aggregation of NP and inhibits its nuclear accumulation. Nucleozin impeded influenza A virus replication in vitro with a nanomolar median effective concentration (EC(50)) and protected mice challenged with lethal doses of avian influenza A H5N1. Viral NP is a valid target for the development of small-molecule therapies[2]. |
细胞实验 | For live imaging, cells were grown in chambered glass bottom dishes and maintained at 37°C in L-15 CO2-independent medium (Gibco) during analysis. Cells were transfected with GFP-NP and infected with PR8 12 h later. For nucleozin treatment, images were acquired for 5 min and then nucleozin was added to a final concentration of 2 μM before imaging for around 20 to 30 min . Images were acquired at 0.25 or 0.71 frame/s and processed with ImageJ[1]. |
别名 | [4-(2-氯-4-硝基苯基)-1-哌嗪基](5-甲基-3-苯基-4-异噁唑基)-甲酮 |
分子量 | 426.85 |
分子式 | C21H19ClN4O4 |
CAS No. | 341001-38-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 28.66 mg/mL (67.14 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3427 mL | 11.7137 mL | 23.4274 mL | 58.5686 mL |
5 mM | 0.4685 mL | 2.3427 mL | 4.6855 mL | 11.7137 mL | |
10 mM | 0.2343 mL | 1.1714 mL | 2.3427 mL | 5.8569 mL | |
20 mM | 0.1171 mL | 0.5857 mL | 1.1714 mL | 2.9284 mL | |
50 mM | 0.0469 mL | 0.2343 mL | 0.4685 mL | 1.1714 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Nucleozin 341001-38-5 Microbiology/Virology Influenza Virus inhibit viral Inhibitor infection nuclear nucleoprotein [4-(2-氯-4-硝基苯基)-1-哌嗪基](5-甲基-3-苯基-4-异噁唑基)-甲酮 virus replication accumulation inhibitor